Now showing items 1-2 of 2

    • Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa 

      Jaoko Walter G.; Nakwagala, Frederick N.; Anzala, Omu; Manyonyi, Gloria Omosa; Birungi, Josephine; Nanvubya, Annet; Bashir, Farah; Bhatta, Kirana; Ogutu, Hilda; Wakasiaka, Sabina; Matu, Lucy; Waruingi, Wambui; Odada, Jane; Oyaro, Micah; Indangasi, Jackton; Ndinya-Achola, JO; Konde, Carol; Mugisha, Emmanuel; Fast, Patricia; Schmidt, Claudia; Gilmour, Jill; Tarragona, Tony; Smith, Carol; Barin, Burc; Dally, Len; Johnson, Bruce; Muluubya, Andrew; Nielsen, Leslie; Hayes, Peter; Boaz, Mark; Hughes, Peter; Hanke, Tom´aˇs; McMichael, Andrew; Bwayo, JJ; Kaleebu, Pontiano (2008)
      Summary: The safety and immunogenicity of plasmid pTHr DNA, modified vaccinia virus Ankara (MVA) human immunodeficiency virus type 1 (HIV-1) vaccine candidates were evaluated in four Phase I clinical trials in Kenya and ...
    • Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: Effects of dosage and route on safety and immunogenicity 

      Peters, Barry S.; Jaoko, Walter; Vardas, Eftyhia; Panayotakopoulos, George; Fast, Patricia; Schmidt, Claudia; Gilmour, Jill; Bogoshi, Mampedi; Omosa-Manyonyi, Gloria; Dally, Len; Klavinskis, Linda; Farah, Bashir; Tarragona, Tony; Bart, Pierre-Alexandre; Robinson, Andrew; Pieterse, Colleen; Stevens, Wendy; Thomas, Richard; Barin, Burc; McMichael, Andrew J.; McIntyre, James A.; Pantaleo, Giuseppe; Hanke, Tom´aˇs; Bwayo, JJ (2007)
      Background: Two parallel studies evaluated safety and immunogenicity of a prophylactic HIV-1 vaccine in 192 HIV-seronegative, low-risk volunteers. Modified vaccinia virus Ankara (MVA) and plasmid DNA (pTHr) expressed HIV-1 ...